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Background:  Clopidogrel  requires  oxidation  dependent  on  the  cytochrome  P450  enzyme  2C19
(CYP2C19) to  form  its  active  metabolite.  The  importance  of  loss-of-function  alleles  (particularly
CYP2C19*2,  681G>A)  in  poor  platelet  response  to  clopidogrel  is  well  recognized.
Objective:  To  investigate  the  prevalence  and  prognostic  impact  of  the  CYP2C19*2  allele  in  a
local acute  coronary  syndrome  (ACS)  population.
Methods:  We  performed  a  prospective,  longitudinal  study  of  95  patients  admitted  for  an  ACS
between  March  and  October  2009  to  a  single  coronary  care  unit.  Patients  aged  under  75  who
survived hospital  stay  and  for  whom  clopidogrel  was  prescribed  were  included.  At  discharge,
CYP2C19  was  genotyped  using  a  commercially  available  kit.  Patients  were  divided  into  two
groups: Group  A  (non-carriers,  normal  metabolizers,  CYP2C19*1/*1),  n  =  69;  and  Group  B  (car-
riers, slow  metabolizers,  CYP2C19*2/*1  or  *2/*2),  n  =  26.  The  primary  endpoint  was  a  combined
outcome  of  cardiovascular  death,  non-fatal  myocardial  infarction  or  re-admission  for  unstable
angina; median  follow-up  was  136.0  (79.0--188.0)  days.
Results:  The  median  age  of  the  population  was  62.0  (51.0--68.0)  years,  and  83.2%  were  male.
The CYP2C19*2  (A)  allele  had  a  frequency  of  14.2%.  There  were  no  differences  between  the
groups with  respect  to  demographic  data  or  history  of  cardiovascular  disease.  Coronary  anatomy,
left ventricular  ejection  fraction  and  renal  function  were  also  similar.  The  groups  were  also
homogenous  with  respect  to  GRACE  risk  score  (118.0  (95.0--136.5)  vs.  115.0  (96.0--133.0),
p =  0.68),  medical  treatment  and  percutaneous  revascularization  during  hospital  stay.  Event-
free survival  was  higher  for  Group  A  (94.0%  vs.  75.0%,  log-rank  p  =  0.010).  Three  readmissionsPlease  cite  this  article  in  press  as:  Teixeira  R,  et  al.  CYP2C19*2  and  prognosis  after  an  acute  coronary  syndrome:  Insights
from  a  Portuguese  center.  Rev  Port  Cardiol.  2012.  doi:10.1016/j.repc.2012.02.001
for MI  were  documented,  all  in  the  slow  metabolizers  group.
Conclusion: In our  ACS  population,  the  CYP2C19*2  allele  was  a  medium-term  prognostic  marker.
© 2010  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Importância  prognóstica  do  alelo  CYP2C19*2  após  uma  síndrome  coronária  aguda:
dados  de  um  centro  nacional
Resumo
Introduc¸ão:  Polimorﬁsmos  no  complexo  enzimático  P450,  como  CYP2C19*2,  681G>A  parecem
estar na  base  de  fraca  resposta  ao  clopidogrel.
Objectivo: Caracterizar  a  prevalência  e  o  impacto  prognóstico  do  alelo  CYP2C19*2(A)  numa
populac¸ão local  de  doentes  com  síndrome  coronária  aguda  (SCA).
Populac¸ão  e  métodos:  Estudo  longitudinal,  prospectivo,  de  95  doentes  admitidos  por  SCA  entre
Marc¸o e  Outubro  de  2009.  Foram  incluídos  doentes  com  idade  inferior  a  75  anos,  que  sobre-
viveram à  hospitalizac¸ão,  e  que  tiveram  alta  medicados  com  clopidogrel.  Foi  determinado  o
genótipo do  alelo  CYP2C19  no  momento  da  alta  hospitalar.  Foram  criados  dois  grupos;  grupo  A
(metabolizadores  normais,  CYP2C19  *1/*1)  n  =  69  e  grupo  B  (metabolizadores  lentos,  CYP2C19
*2/*1 ou  *2/*2)  n  =  26.  No  seguimento  foi  analisado  um  resultado  combinado  de  morte  cardiovas-
cular, enfarte  agudo  do  miocárdio  não  fatal,  e  readmissão  por  angina  instável  (tempo  mediano
de seguimento:  136  (79--188)  dias.
Resultados:  A  idade  mediana  da  populac¸ão  era  de  62,0  (51,0--68,0)  anos,  e  83,2%  eram
do género  masculino.  O  alelo  CYP2C19*2(A)  teve  uma  frequência  de  14,2%.  Não  existiram
diferenc¸as entres  os  grupos  relativamente  a  dados  demográﬁcos,  e  antecedentes  cardio-
vasculares.  A  anatomia  coronária,  a  fracc¸ão  de  ejecc¸ão  ventricular  esquerda  e  a  func¸ão
renal eram  semelhantes.  Os  grupos  eram  também  homogéneos  relativamente  ao  score  GRACE
(118,0 (95,0--136,5)  versus  115,0  (96,0--133,0),  p  =  0,68),  tratamento  médico  e  taxa  de
revascularizac¸ão percutânea  durante  hospitalizac¸ão.  No  ﬁnal  do  seguimento  clínico  a  sobre-
vida livre  de  eventos  foi  superior  para  o  grupo  A  (94,0%  versus  75,0%,  log  rank  p  =  0,010).  Foram
documentadas  três  readmissões  por  enfarte  agudo  do  miocárdio,  todas  no  grupo  B.
Conclusões:  Na  populac¸ão  referida,  o  alelo  CYP2C19*2  (A)  foi  um  marcador  de  prognóstico  a
médio prazo.

















































ual  antiplatelet  therapy  with  aspirin  and  clopidogrel
ppears  to  offer  synergistic  beneﬁt  in  preventing  thrombus
ormation,  but  up  to  15%  of  high-risk  acute  coro-
ary  syndrome  (ACS)  patients  continue  to  suffer  from
schemic  events.1 A  recent  meta-analysis  found  an  overall
revalence  of  21%  of  laboratory  deﬁned  clopidogrel  non-
esponsiveness.2 The  mechanisms  leading  to  poor  response
o  clopidogrel  and  therefore  to  high  platelet  reactivity
HPR)  have  not  been  fully  elucidated  and  are  proba-
ly  multifactorial.  Compliance,  cellular,  environmental,
enetic  and  clinical  factors  such  as  obesity,  diabetes
ellitus,  nature  of  coronary  injury  and  inﬂammation
re  known  to  contribute  to  variable  antiplatelet  drug
esponse.3
Response  to  clopidogrel  may  be  inﬂuenced  by  pharma-
okinetic  variables  such  as  intestinal  absorption,  metabolic
ctivation  in  the  liver,  and  biologic  activity.4 Clopidogrel  is
 prodrug  and  requires  oxidation  that  is  mainly  dependent
n  the  cytochrome  P450  enzymes  2C19  (CYP2C19)  and  to  a
esser  extent  the  isoenzymes  CYP2C9,  3A4,  3A5  and  2B6.5
round  25  genetic  variants  in  CYP2C19  have  been  found
www.cypalleles.ki.se).  The  presence  of  the  loss-of-function
81G>A  polymorphism  (*2),  a  single-nucleotide  polymor-Please  cite  this  article  in  press  as:  Teixeira  R,  et  al.  CYP2C19*2
from  a  Portuguese  center.  Rev  Port  Cardiol.  2012.  doi:10.1016/
hism  (SNP)  (rs4244285)  in  exon  5  mapped  to  the  long  arm  of
hromosome  10  (10q24.1--q24.3),6 is  associated  with  clopi-
ogrel  responsiveness  in  healthy  individuals7 and  in  patients
ith  coronary  artery  disease.8,9
s
s
tCarriers  of  a  reduced-function  CYP2C19  genomic  vari-
nt  treated  with  clopidogrel  for  an  ACS  or  by  percutaneous
oronary  intervention  (PCI)  probably  have  a  worse  ischemic
utcome,  as  was  reported  in  a  recent  meta-analysis  that
ncluded  9685  patients.10 By  contrast,  data  from  2208
atients  in  FAST-MI  (French  Registry  of  Acute  ST-Elevation
nd  Non-ST-Elevation  Myocardial  Infarction)  did  not  iden-
ify  carriers  of  a  single  loss-of-function  allele  in  CYP2C19
ith  a  worse  ischemic  endpoint,  although  a  signiﬁcantly
igher  event  rate  was  noted  for  carriers  of  any  two  or
ore  loss-of-function  alleles.4 A  negative  result  was  noted
n  the  CHARISMA  (Clopidogrel  for  High  Atherothrombotic
isk  and  Ischemic  Stabilization,  Management  and  Avoid-
nce)  genomic  analysis,  as  no  relationship  was  seen  between
YP2C19*2  heterozygotes  and  ischemic  outcomes,  although
YP2C19*2  homozygotes  had  a  worse  prognosis.11
In  this  context,  we  decided  to  evaluate  the  frequency  and
edium-term  prognostic  impact  of  the  CYP2C19*2  allele  in
 local  single-center  Portuguese  ACS  cohort.
ethods
tudy  design  and  eligibility
e  performed  a  prospective  longitudinal  study  of  95  con- and  prognosis  after  an  acute  coronary  syndrome:  Insights
j.repc.2012.02.001
ecutive  patients  admitted  for  an  ACS  who  survived  hospital
tay  between  April  and  October  2009.
The  local  ethics  committee  approved  the  research  pro-
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CYP2C19*2  and  prognosis  after  an  acute  coronary  syndrome  
To  be  eligible,  patients  had  to  be  less  than  75  years  old
and  be  discharged  on  clopidogrel  therapy  (75  mg/day).
Patients  were  excluded  if  they  were  immediately
referred  for  surgery,  or  if  they  were  included  in  either  of
two  clinical  trials  related  to  anti-platelet  therapy  --  TRA*CER
(Trial  to  Assess  the  Effects  of  SCH  530348  in  Preventing
Heart  Attack  and  Stroke  in  Patients  With  Acute  Coronary
Syndrome12 --  ClinicalTrials.gov  identiﬁer:  NCT00527943)
and  TRILOGY  ACS  (A  Comparison  of  Prasugrel  and  Clopidogrel
in  Acute  Coronary  Syndrome  Subjects  --  ClinicalTrials.gov
identiﬁer:  NCT00699998).
ST-elevation  myocardial  infarction  was  deﬁned  as
ischemic  chest  pain  associated  with  new-onset  ST  elevation
in  the  ECG  greater  than  1  mm  in  at  least  two  contiguous
leads.
Non-ST  elevation  myocardial  infarction  was  deﬁned  as
ischemic  chest  pain  lasting  more  than  ﬁve  minutes,  and  posi-
tive  cardiac  biomarkers  (troponin  I)  with  or  without  ischemic
ECG  changes  (ST  depression  or  T-wave  inversion).
Unstable  angina  was  deﬁned  as  new  onset  angina  (at  least
CCS  class  III),  progressive  angina,  or  angina  at  rest,  with  or
without  ischemic  ECG  changes.
The  clopidogrel  loading  dose  was  determined  by  the  car-
diologist  in  the  emergency  department,  and  the  subsequent
daily  and  discharge  dosage  was  75  mg  per  day.  The  aspirin
loading  dose  was  determined  similarly,  with  a  subsequent
and  discharge  dosage  of  100  mg  per  day.
Platelet  function  tests  were  performed  at  discharge.
Clopidogrel  responsiveness  was  tested  using  multiple  elec-
trode  aggregometry  (MEA),  on  a  Multiplate  analyzer®.13 MEA
was  assessed  in  whole  blood;  ADP  was  used  as  agonist  and
the  results  were  expressed  in  arbitrary  units  (U).14
Baseline  and  follow-up  data
Standardized  records  at  admission  included  demographic,
clinical,  electrical  and  laboratory  data.  Medical  therapy,
catheterization  data,  in-hospital  events  and  discharge  med-
ication  were  also  recorded.
Median  clinical  follow-up  was  136.0  (79.0--188.0)  days
after  hospital  discharge.  The  information  was  collected  by
telephone,  from  hospital  records  or  at  the  outpatient  clinic.
The  primary  endpoint  analyzed  was  the  combined  outcome
of  cardiovascular  death,  non-fatal  myocardial  infarction  or
re-admission  for  unstable  angina.
Genotyping
Genomic  DNA  was  extracted  at  hospital  discharge  from
peripheral  blood  leukocytes.
CYP2C19*1  (wild  type)  and  CYP2C19*2  (681G>A),  two
SNPs  in  the  CYPC2C19  gene,  were  genotyped  using  a
commercial  kit  from  Seegene®.
The  technique  employed  is  based  on  dual  priming
oligonucleotide  (DPO)  polymerase  chain  reaction  (PCR).  DPO
PCR  consists  of  two  separate  priming  regions  joined  by  a
polydeoxyinosine  linker.  This  linker  is  not  involved  in  prim-Please  cite  this  article  in  press  as:  Teixeira  R,  et  al.  CYP2C19*2
from  a  Portuguese  center.  Rev  Port  Cardiol.  2012.  doi:10.1016/
ing  but  rather  in  delineating  the  boundary  between  the
two  parts  of  the  primer.  In  the  ﬁrst  priming  reaction  the
longer  5′ segment  binds  to  the  template  DNA,  initiating  sta-






egment  selectively  binds  to  a  target  site  and  determines  a
arget-speciﬁc  extension,  acting  as  a  determiner.  Conven-
ional  primers  have  a  single  priming  region  and  extension
ay  proceed  even  in  the  presence  of  mismatches  between
 primer  and  a  template.  The  new  methodology  used  is  a
undamental  tool  for  blocking  extension  of  non-speciﬁcally
rimed  templates,  generating  consistently  high  PCR  speci-
city,  as  previously  described  for  CYP2C19  SNPs.15
A  commercial  genomic  DNA  extraction  kit  was  used  in
rder  to  obtain  60--100  ng  of  isolated  DNA  for  PCR.  Ampliﬁca-
ion  was  performed  in  a  ﬁnal  volume  of  20  l  in  accordance
ith  the  manufacturer’s  instructions.  It  contained  4  l  of
NA  solution,  3  l MOP  solution,  10  l 2×  Multiplex  Master
ix  (Seegene,  Seoul,  Korea)  and  3  l of  template.
The  reaction  started  after  an  initial  preheating  step  at
4 ◦C  for  ﬁfteen  minutes,  followed  by  35  ampliﬁcation  cycles
n  the  thermal  cycler  under  the  following  conditions:  denat-
ration  at  94 ◦C  for  30  s,  annealing  at  63 ◦C  for  30  s,  and
xtension  at  72◦ C  for  30  s.  Ampliﬁcation  was  completed  with
 ﬁnal  extension  step  at  72 ◦C  for  5  min.  PCR  ﬂuorescence
ield  for  the  two  different  dyes  was  measured  to  obtain  the
llelic  discrimination  plot  and  to  identify  individual  geno-
ypes  and  was  presented  on  a  2-dimensional  graph.
Due  to  the  low  number  of  CYP2C19*2  homozygotes,  most
f  the  analysis  was  based  on  the  comparison  of  CYP2C19*2
*2/*1  or  *2/*2)  carriers  and  wild  type  homozygotes  (*1/*1).
atients  were  divided  into  two  groups:  Group  A  (non-
arriers),  n  =  69;  and  Group  B  (carriers),  n  =  26.
tatistical  analysis
ontinuous  data  are  presented  as  median  and  interquartile
ange  and  groups  were  compared  with  the  Mann--Whitney
est.  Categorical  variables  are  reported  as  frequencies  and
ercentages,  and  the  chi-square  test  or  Fisher’s  exact  test
as  used  as  appropriate.
Deviation  from  Hardy--Weinberg  equilibrium  in  the
YP2C19  polymorphism  was  tested  with  the  chi-square  test.
Cumulative  survival  curves  were  constructed  by  the
aplan--Meier  method  and  groups  were  compared  with  the
og-rank  test.  The  observational  period  started  at  hospital
ischarge.
Multivariate  Cox  regression  analysis  was  performed  for
he  primary  endpoint.  Variables  that  were  signiﬁcant  at  the
ivariate  level  (with  a p  value  below  0.10)  and  that  had
linical  relevance  were  included  in  the  model.
All  statistical  tests  were  two-tailed  and  a  p  value  less  than
.05  was  deemed  signiﬁcant.  The  analysis  was  performed
ith  SPSS  (Statistical  Package  for  the  Social  Sciences)  ver-
ion  15,  SPSS  Inc.,  Chicago,  IL.
esults
he  median  age  of  the  population  was  62.0  (51.0--68.0)  years
ith  a  predominance  of  males  (83.2%).  All  were  Caucasian.
Of  the  95  patients  included,  69  (72.6%)  were  wild-type
omozygous  (*1/*1),  25  (26.3%)  were  heterozygous  with and  prognosis  after  an  acute  coronary  syndrome:  Insights
j.repc.2012.02.001
espect  to  the  *2  allelic  variant  (*1/*2),  and  one  (1.1%)  was
omozygous.  The  allelic  frequency  of  the  CYP2C19*2  (A)
llele  was  14.2%,  and  was  85.8%  for  CYP2C19*1  (G).  No  devi-
tion  was  noted  from  the  expected  proportions  of  genotypes
ARTICLE IN PRESS+ModelREPC-68; No. of Pages 9
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Table  1  Baseline  characteristics.
CYP2C19*2  allele  p
Overall  Non-carriers  Carriers
No.  of  patients  95  69  26
Male gender  (%)  79/95  (83.2)  58/69  (84.1)  21/26  (80.8)  0.70
Age (median,  IQ  range)  62.0  (51.0--68.0)  62.0  (51.0--68.0)  60.5  (52.0--71.3)  0.87
Admission diagnosis  (%)
STEMI  36/95  (37.9)  25/69  (36.2)  11/26  (42.3)  0.59
NSTEMI 33/95  (34.7)  28/69  (40.6)  5/26  (19.2)  0.051
UA 26/95  (27.4)  16/69  (23.2)  10/26  (38.5)  0.14
Cardiovascular  risk  factors  (%)
Diabetes 30/95  (31.6)  21/69  (30.4)  9/26  (34.6)  0.70
Dyslipidemia  59/95  (62.1)  47/69  (68.1)  12/26  (46.2)  0.05
Hypertension  73/95  (76.8)  55/69  (79.7)  18/26  (69.2)  0.28
Current smoking  19/95  (20.0)  12/69  (17.4)  7/26  (26.9)  0.30
Cardiovascular  history  (%)
Previous  MI  19/95  (20.0)  14/69  (20.3)  5/26  (19.2)  0.91
Previous PCI  13/95  (13.7)  10/69  (14.5)  3/26  (11.5)  0.69
Previous CABG  4/95  (4.2)  2/69  (2.9)  2/26  (7.7)  0.31
Previous medication  (%)
Aspirin 38/95 (40.0)  27/69 (39.1)  11/26 (42.3)  0.78
Clopidogrel 16/95 (16.8)  5/26 (19.2)  11/69 (15.9)  0.70
Beta-blockers  23/95  (24.2)  19/69  (27.5)  4/26  (15.4)  0.22
ACE inhibitors  46/95  (48.4)  33/69  (47.8)  13/26  (50.0)  0.85
Statins 44/95  (46.3)  35/69  (50.7)  9/26  (34.6)  0.16
Diuretics 16/95  (16.8)  14/69  (20.3)  2/26  (7.7)  0.14
Nitrates 8/95  (8.4)  6/69  (8.7)  2/26  (7.7)  0.88






































iST elevation myocardial infarction; PCI: percutaneous coronary i
angina.
n  the  population  predicted  by  Hardy--Weinberg  equilibrium
or  polymorphisms  (p  =  0.44).
There  were  no  signiﬁcant  differences  in  terms  of  demo-
raphics,  admission  diagnosis,  cardiovascular  history  or
ardiovascular  risk  factors,  with  the  exception  of  previous
yslipidemia,  which  was  more  prevalent  in  the  non-carrier
roup  (Table  1).
The  groups  were  similar  regarding  risk  assessment
ccording  to  the  TIMI  and  GRACE  risk  scores.  Other  variables
uch  as  body  weight,  left  ventricular  ejection  fraction,  peak
roponin  I,  admission  and  nadir  hemoglobin,  and  glomerular
ltration  rate  were  also  homogenous  for  both  populations.
latelet  function  assessed  at  discharge  was  similar  for  both
roups  (Table  2).
Almost  three-quarters  of  both  sub-populations  were
reated  by  an  invasive  strategy.  Most  had  single-vessel  dis-
ase,  and  drug-eluting  stents  were  used  in  both  groups
Table  3).
edical  therapyPlease  cite  this  article  in  press  as:  Teixeira  R,  et  al.  CYP2C19*2
from  a  Portuguese  center.  Rev  Port  Cardiol.  2012.  doi:10.1016/
ith  respect  to  medical  therapy,  almost  all  of  the  population
97.9%)  started  on  clopidogrel  and  aspirin  during  the  ﬁrst
4  hours.  Only  a  third  of  the  patients  received  a  loading  dose
f  clopidogrel.  The  most  used  anticoagulant  was  enoxaparin.
n
l
tention; STEMI: ST elevation myocardial infarction; UA: unstable
ondaparinux  was  used  less  frequently  in  non-carriers  (5.8
s.  19.2%,  p  =  0.049).  There  were  no  signiﬁcant  differences
egarding  medication  in  the  ﬁrst  24  hours  or  at  discharge
Table  4).
ollow-up  and  multivariate  analysis
ollow-up  data  were  available  for  91  patients  (4.2%  lost  to
ollow-up).  Median  follow-up  for  the  whole  population  was
36.0  (79.0--188.0)  days.
Ten  primary  endpoint  events  were  recorded  during
ollow-up.  One  patient  died,  three  had  a  non-fatal  myocar-
ial  infarction,  and  six  were  readmitted  for  unstable  angina
uring  follow-up.  The  primary  endpoint  was  reached  by  four
f  the  67  homozygous  patients,  as  opposed  to  six  of  the  24
eterozygotes.  Event-free  survival  curves  for  both  groups
re  presented  in  Fig.  1.  This  result  was  signiﬁcant  (log-rank
 =  0.010).
With  analysis  based  solely  on  the  combined  out-
ome  of  cardiovascular  mortality  and  non-fatal  myocardial
nfarction,  freedom  from  the  combined  event  remained  sig- and  prognosis  after  an  acute  coronary  syndrome:  Insights
j.repc.2012.02.001
iﬁcantly  lower  for  the  *2  carrier  population  (98.5  vs.  87.5%,
og-rank  p  =  0.026)  (Fig.  2).
In  univariate  analysis  of  the  combined  endpoint,  only
he  presence  of  CYP2C19*2,  diabetes,  and  a  higher  level
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Table  2  Hemodynamic,  electrical  and  laboratory  data.
CYP2C19*2  allele  p
Overall  Non-carriers  Carriers
Hemodynamic  data  on  admission
Heart  rate,  bpm  (mean,  SD)  72.0  (68.5--80.0)  72.0  (69.0--80.0)  74.0  (68.0--80.0)  0.96
SBP, mmHg  (mean,  SD)  140.0  (123.5--150.0)  140.0  (120.0--150.0)  139.0  (130.0--158.5)  0.11
DBP, mmHg  (mean,  SD)  79.0  (70.0--82.5)  70.0  (68.0--80.0)  80.0  (77.5--90.0)  0.007
TIMI risk  score  ≤2  (%)  57/95  (60.0)  39/69  (56.5)  18/26  (69.2)  0.26
TIMI risk  score  3--4  (%)  32/95  (33.7)  25/69  (36.2)  7/26  (26.9)  0.71
TIMI risk  score  ≥5  (%) 6/95 (6.3)  5/69  (7.2)  1/26  (3.8)  0.54
GRACE risk  score 117.5 (95.2--133.0) 118.0 (95.0--136.5) 115.0 (96.0--133.0)  0.68
Body mass  index  (kg/m2)  27.7 (25.9--29.5) 27.7 (26.3--29.9) 27.5 (25.6--29.4) 0.34
LVEF  (%)  55.0  (50.0--60.3)  58.0  (49.0--60.0)  55.0  (51.0--63.0)  0.15
Electrical data  on  admission  (%)
Sinus  rhythm 91/94  (96.8)  66/68  (97.1)  25/26  (96.2)  0.83
AF 2/94  (2.1)  1/68  (1.5)  1/26  (3.8)  0.48
ST depression 21/94 (22.3)  13/68  (19.1)  8/26  (30.8)  0.53
T-wave inversion 12/94 (12.8)  9/68 (13.2)  3/26  (11.5)  0.83
Laboratory data  (mean,  SD)
Peak  troponin  I,  ng/ml  12.1  (3.4--38.6)  13.9  (4.8--38.8)  10.5  (3.4--126.7)  0.58
Peak CKMB  mass,  U/l  29.3  (8.8--98.7)  38.5  (10.8--94.8)  38.8  (6.6--149.9)  0.85
Total cholesterol,  mg/dl  191.0  (155.7--223.5)  182.0  (155.5--217.5)  206.0  (155.5--142.5)  0.40
LDL cholesterol,  mg/dl  128.0  (99.8--157.5)  135.0  (99.5--155.5)  128.0  (99.5--176.0)  0.30
Glomerular  ﬁltration  rate,  ml/min/m2 79.2  (63.7--106.9)  81.4  (63.6--106.7)  73.6  (63.7--114.1)  0.99
Peak CRP,  mg/dl  1.8  (0.48--6.35)  2.07  (0.55--7.17)  1.15  (0.44--3.96)  0.33
Admission hemoglobin,  g/dl  13.5  (12.0--14.5)  13.3  (12.0--14.4)  13.6  (12.1--14.8)  0.23
Minimum hemoglobin,  g/dl  12.6  (11.4--13.7)  12.4  (11.4--13.3)  12.7  (11.6--13.8)  0.48






CAF: atrial ﬁbrillation; CRP: C-reactive protein; DBP: diastolic bloo
pressure.
of  C-reactive  protein  (CRP)  were  signiﬁcant.  According  to
the  Cox  regression  model,  only  the  presence  of  CYP2C19*2
was  an  independent  predictor  of  outcome,  conferring  a
4.65  increase  in  relative  risk  (95%  conﬁdence  interval  [CI]
1.28--16.8,  p  =  0.019)  (Table  5).
DiscussionPlease  cite  this  article  in  press  as:  Teixeira  R,  et  al.  CYP2C19*2
from  a  Portuguese  center.  Rev  Port  Cardiol.  2012.  doi:10.1016/
Our  study  conﬁrms  the  prognostic  importance  of  the  *2
polymorphism  in  CYP2C19,  as  in  a  Portuguese  single-





Table  3  In-hospital  management.
Overall  
Invasive  strategy  (%)  73/95  (76.8)  
Non-signiﬁcant  coronary  stenosis  (%)  12/73  (16.4)  
One-vessel disease  (%)  32/73  (43.8)  
Two-vessel disease  (%)  11/73  (15.1)  
Three-vessel  disease  (%)  18/73  (24.7)  
Stent (%)  44/73  (60.3)  
Drug-eluting  stent  (%)  34/44  (78.3)  ssure; LVEF: left ventricular ejection fraction; SBP: systolic blood
ntiplatelet  therapy,  this  SNP  conferred  less  protection  from
ecurrent  cardiac  ischemic  events.
YP2C19*2  frequency
ur  local  data  were  in  agreement  with  previous  studies  on
aucasians  populations  that  reported  *2  frequencies  rang- and  prognosis  after  an  acute  coronary  syndrome:  Insights
j.repc.2012.02.001
ng  from  11.1  to  15.9%.16--18 Our  CYP2C19*2  frequency  of
4.2%  was  lower  than  others,  particularly  in  an  Asian  cohort
n  which  the  frequency  of  CYP2C19*2  reached  45%.19 The
YP2C19*3  allele  was  not  found  in  any  patient  in  our  cohort
CYP2C19*2  allele  p
Non-carriers  Carriers
55/69  (79.7)  18/26  (69.2)  0.28
10/54  (18.5)  2/19  (10.5)  0.42
22/55  (40.0)  10/18  (55.6)  0.25
10/55  (18.2)  1/18  (5.6)  0.19
13/55  (23.6)  5/18  (27.8)  0.72
32/55  (58.2)  12/18  (66.7)  0.52
25/32  (78.1)  9/12  (75.0)  0.83
Please  cite  this  article  in  press  as:  Teixeira  R,  et  al.  CYP2C19*2  and  prognosis  after  an  acute  coronary  syndrome:  Insights
from  a  Portuguese  center.  Rev  Port  Cardiol.  2012.  doi:10.1016/j.repc.2012.02.001
ARTICLE IN PRESS+ModelREPC-68; No. of Pages 9
6  R.  Teixeira  et  al.
Table  4  Medical  therapy.
CYP2C19*2  allele  p
Overall  Non-carriers  Carriers
Anti-platelet  and  anti-thrombotic  medication  in  the  ﬁrst  24  hours  (%)
Aspirin 93/95  (97.9)  68/69  (98.6)  25/26  (96.2)  0.47
Clopidogrel 94/95  (98.9)  68/69  (98.6)  26/26  (100.0)  0.54
Loading dose  clopidogrel  33/95  (34.7)  21/69  (30.4)  12/26  (46.2)  0.17
LMWH 71/95  (74.7)  49/69  (71.0)  22/26  (84.6)  0.17
Fondaparinux  9/95  (9.5)  4/69  (5.8)  5/26  (19.2)  0.049
GP IIb/IIIa  inhibitors 30/95  (31.6)  23/69  (33.3)  7/26  (26.9)  0.28
Anti-ischemic  medication  in  the  ﬁrst  24  hours  (%)
Beta-blockers 87/84 (92.6)  64/68 (94.1)  23/26 (88.5)  0.35
Nitrates 12/94  (12.8)  10/68  (14.7)  2/26  (7.7)  0.36
Calcium channel  blockers  11/94  (11.7)  7/68  (10.3)  4/26  (15.4)  0.49
Other therapy  in  the  ﬁrst  24  hours  (%)
ACE  inhibitors/ARBs 91/94  (96.8)  65/68  (95.6)  26/26  (100.0)  0.28
Statins 94/94 (100.0)  68/68  (100.0)  26/26  (100.0)  1.00
Diuretics 8/94 (8.5)  7/68 (10.3)  1/26  (3.8)  0.32
PPIs 55/95 (57.9)  40/69 (58.0)  15/26 (57.7)  0.98
Medical therapy  at  discharge  (%)
Aspirin  92/95  (96.8)  67/69  (97.1)  25/26  (96.2)  0.89
Clopidogrel 95/95  (100.0)  69/69  (100.0)  26/26  (100.0)  1.00
Beta-blockers  82/95  (86.3)  62/69  (89.9)  20/26  (76.9)  0.10
ACE inhibitors/ARBs  88/95  (92.6)  63/69  (91.3)  25/26  (96.2)  0.42
Statins 88/95  (92.6)  64/69  (92.8)  24/26  (92.3)  0.94
ACE: angiotensin-converting enzyme; ARBs: angiotensin receptor blockers; GP: glycoprotein; LMWH: low molecular weight heparin; PPI:
proton pump inhibitors.
Table  5  Univariate  predictors  of  the  combined  event.
No  event  Event  OR  (95%  CI)  p
No.  81  10
Female gendera 13/81  (16.0)  3/10  (30.0)  2.24  (0.51--9.82)  0.27
STEMIa 31/81  (38.3)  4/10  (40.0)  1.08  (0.28--4.12)  0.92
Diabetesa 23/81  (28.4)  7/10  (70.0)  5.89  (1.40--24.7)  0.008
Previous myocardial  infarctiona 17/81  (21.0)  2/9  (22.2)  1.08  (0.21--5.67)  0.91
CYP2C19*2 carriersa 18/81  (22.2)  6/10  (60.0)  5.25  (1.36--20.65)  0.011
Invasive strategya 19/81  (23.5)  2/10  (20.0)  0.81  (0.16--4.17)  0.81
Multivessel disease  25/62  (40.3)  4/8  (50.0)  1.48  (0.34--6.48)  0.61
Clopidogrel loading  dosea 32/81  (39.5)  2/10  (40.0)  1.02  (0.27--3.90)  0.98
PPIa 48/81  (59.3)  5/10  (50.0)  0.69  (0.18--2.56)  0.58
Age (years)b 60.3  ±  10.9  60.2  ±  9.5  0.98
LVEF (%)b 54.4  ±  11.2  59.8  ±  8.6  0.14
C-reactive protein,  mg/dlb 3.5  ±  4.1  6.9  ±  7.7  0.027
Glomerular ﬁltration  rate,  ml/min/m2b 88.9  ±  35.8  79.5  ±  36.1  0.39
Peak troponin  I,  ng/ml  31.1  ±  59.4  16.7  ±  20.5  0.56
Platelet aggregation,  U  17.5  ±  5.9  20.3  ±  4.6  0.24
Multivariate  Cox  regression  analysis  for  the  composite  endpoint  at  follow-up
Variables  HR  p  value  95%  CI
CYP2C19*2 carriers  4.65  0.019  1.28--16.8
Diabetes 3.99  0.053  0.98--16.3
C-reactive protein  ≥  5.2  mg/dl  2.74  0.124  0.76--9.87
Chi-square 16.9; p < 0.01.
LVEF: left ventricular ejection fraction; PPI: proton pump inhibitor; STEMI: ST elevation myocardial infarction.
a %.
b Mean ± SD.
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aFigure  1  Kaplan--Meier  curves  representing  six-month  event-
free survival.
(data  not  shown),  which  has  also  been  reported  in  Caucasian
cohorts  by  Scordo  et  al.16 and  Goldstein  et  al.18
Mechanism
There  are  compelling  biologic  data  to  support  the
association  between  CYP2C19*2  and  prognosis.  CYP2C19
contributes  to  both  of  the  sequential  oxidative  metabolic
steps  of  clopidogrel  activation.  Slowing  the  ﬁrst  reac-
tion  would  tend  to  shunt  the  prodrug  preferentially  to
an  esterase-mediated  pathway  forming  pharmacologically
inactive  metabolites.20 Although  there  are  many  genetic
polymorphisms  of  CYP2C19,  the  *2  allele  was  the  most
frequent  variant  in  the  reduced-function  group.  This  loss-of-
function  variant  encodes  a  cryptic  splice  variant  that  leads
to  no  enzymatic  activity.21
Decreased  CYP2C19  activity  leads  to  decreased  exposure
to  the  active  metabolite  of  clopidogrel  and  to  reduced  phar-
macodynamic  response  that  is  probably  the  basis  of  HPR.15,22Please  cite  this  article  in  press  as:  Teixeira  R,  et  al.  CYP2C19*2
from  a  Portuguese  center.  Rev  Port  Cardiol.  2012.  doi:10.1016/
HPR  has  been  documented  after  a  loading  dose  of  clopido-
grel,  but  also  after  75  mg  clopidogrel  per  day  for  one  week.23
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Figure  2  Kaplan--Meier  curves  representing  six-month  event-




















hat  ADP-induced  platelet  aggregation  was  not  statistically
ifferent  in  the  two  patient  groups.
Another  explanation  for  the  prognostic  impact  of  the
NP  studied  was  the  association  between  CYP2C19*2  and
igher  concentrations  of  inﬂammatory  markers,  notably
nterleukin-6  and  high  sensitivity  CRP.24 CYP2C19*2  could
herefore  affect  underlying  cardiovascular  risk  in  addition  to
ts  pharmacogenetic  effect  on  clopidogrel.25 However,  in  the
AST-MI  trial,  no  such  effect  was  seen  in  the  subgroup  of  222
atients  who  contributed  a  blood  sample  to  the  DNA  bank
ut  who  did  not  receive  clopidogrel,4 suggesting  that  the
rognostic  implications  of  the  CYP2C19  polymorphism  were
robably  due  to  its  inﬂuence  on  clopidogrel  metabolism.
rognostic  implications
he  magnitude  of  the  effect  of  carriage  of  the  CYP2C19*2
llele  on  prognosis  in  our  population  was  higher  than
xpected  from  recent  trials20 and  even  from  a  collaborative
etanalysis26 (HR  1.6  for  an  endpoint  of  major  cardiovas-
ular  events  with  respect  to  carriers  of  the  *2  allele  vs.
on-carriers).  Nevertheless,  our  data  were  similar  to  those
f  Collet  et  al.,25 in  which  carriers  of  the  CYP2C19*2  allele
ad  a  four  times  higher  rate  of  the  cardiac  ischemic  endpoint
HR  4.6  for  an  endpoint  of  cardiovascular  death,  myocardial
nfarction,  and  myocardial  revascularization).
By  contrast,  previous  trials  concluded  that  CYP2C19*2  by
tself  was  not  an  independent  predictor  of  outcome,  among
hem  the  FAST-MI  study,  in  which  no  SNPs  in  CYP2C19,  or
n  CYP3A5,  P2RY12, or  ITGB3, were  associated  with  the
rimary  outcome.  Of  note  and  probably  explaining  these
esults,  many  demographic  and  clinical  characteristics  dif-
ered  between  patients  who  had  the  primary  outcome  and
hose  who  did  not.  Speciﬁcally,  those  that  had  the  primary
utcome  (294  patients  [13%])  were  older,  had  more  comor-
idities,  were  more  likely  to  be  receiving  drugs  for  secondary
revention  (including  clopidogrel)  before  their  infarction,
nd  were  less  likely  to  receive  primary  PCI  or  intravenous
brinolysis  during  the  inclusion  event.4
Reports  from  substudies  of  the  EXCELSIOR  (Impact
f  Extent  of  Clopidogrel-Induced  Platelet  Inhibition  Dur-
ng  Elective  Stent  Implantation  on  Clinical  Event  Rate)
nd  CLARITY-TIMI  28  (Clopidogrel  as  Adjunctive  Reperfu-
ion  Therapy-Thrombolysis  in  Myocardial  Infarction)  trials
lso  found  no  association  between  CYP2C19  genotype  and
rognosis.27,28
It  also  seems  that,  as  shown  by  the  collaborative  meta-
nalysis,  CYP2C19*2  has  a  greater  impact  in  the  context  of  an
CS  and  percutaneous  revascularization,  in  terms  not  only  of
tent  thrombosis  but  also  of  cardiac  ischemic  endpoints.26 In
AST-MI  and  CLARITY-TIMI  28,  trials  in  which  carriers  of  the
YP2C19*2  did  not  have  a  worse  prognosis,  only  70%  and  58%
f  patients,  respectively,  underwent  PCI.4,27
uture  prospects
here  appears  to  be  agreement  that  CYP2C19*2  carriers and  prognosis  after  an  acute  coronary  syndrome:  Insights
j.repc.2012.02.001
ave  worse  ischemic  outcomes  and  are  more  prone  to  stent
hrombosis.
One  question  that  arises  is  who  should  be  tested.  There
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 history  of  stent  thrombosis,  premature  cardiovascular  dis-
ase,  or  frequent  readmissions  for  ACS  would  appear  to  be
andidates  for  genetic  testing.
Another  issue  is  how  to  manage  CYP2C19*2  and  clopido-
rel  therapy.  Should  the  daily  dosage  be  increased?  Should
 different  antiplatelet  agent  such  as  prasugrel  be  used?
t  present  there  is  insufﬁcient  evidence  to  answer  to  this
uestion.
Finally,  the  interplay  between  platelet  function  testing
nd  clopidogrel  genotyping  is  still  not  clear.  Should  platelet
unction  testing  be  used  to  determine  whether  genome  stud-
es  are  required?  Or,  on  the  contrary,  should  platelet  function
e  assessed  only  after  genotyping  indicates  the  need?
In  the  future,  large-scale  trials  to  test  genetic  strategies
ould  provide  answers  to  these  questions.
imitations
lasma  concentrations  of  the  active  metabolite  of  clopido-
rel  (R130,964)  were  not  measured.  The  small  population
ize  made  it  impossible  to  determine  the  prognostic  impor-
ance  of  CYP2C19  genotyping  regarding  other  outcomes  such
s  stent  thrombosis  and  bleeding  complications.  Sample  size
ay  also  have  been  responsible  for  the  fact  that  platelet
unction  tests  did  not  differ  between  the  groups.  The  low
vent  rate  negatively  inﬂuenced  the  quality  of  the  multi-
ariate  analysis.  Drug  compliance  during  follow-up  was  not
ssessed.
onclusions
n  a  single-center  ACS  population,  the  CYP2C19*2  allele  was
n  independent  prognostic  marker,  conferring  a  4.7  higher
elative  risk  of  a  cardiac  ischemic  endpoint  in  medium-term
ollow-up.
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